


# BIOACTIVE PEPTIDES

Applications  
for Improving  
Nutrition  
and Health



Richard Owusu-Apenten



CRC Press  
Taylor & Francis Group

# BIOACTIVE PEPTIDES

Applications  
for Improving  
Nutrition  
and Health

Richard Owusu-Apesei



CRC Press  
Taylor & Francis Group  
Boca Raton London New York

CRC Press is an imprint of the  
Taylor & Francis Group, an **informa** business

CRC Press  
Taylor & Francis Group  
6000 Broken Sound Parkway NW, Suite 300  
Boca Raton, FL 33487-2742

© 2010 by Taylor and Francis Group, LLC  
CRC Press is an imprint of Taylor & Francis Group, an Informa business

No claim to original U.S. Government works

Printed in the United States of America on acid-free paper  
10 9 8 7 6 5 4 3 2 1

International Standard Book Number: 978-1-4398-1362-1 (Hardback)

This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint.

Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access [www.copyright.com](http://www.copyright.com) (<http://www.copyright.com/>) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

**Trademark Notice:** Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

---

**Library of Congress Cataloging-in-Publication Data**

---

Owusu-Apenten, R. K.

Bioactive peptides : applications for improving nutrition and health / Richard Owusu-Apenten.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-1-4398-1362-1 (hardcover : alk. paper)

1. Peptide drugs. 2. Dietary supplements. 3. Proteins--Metabolism. 4. Proteins in human nutrition. 5. Appetite stimulants. I. Title.

[DNLM: 1. Peptides--therapeutic use. 2. Dietary Supplements. 3. Nutritional Physiological Phenomena. 4. Peptides--pharmacology. 5. Wasting Syndrome--diet therapy. 6. Wasting Syndrome--etiology. QU 68 O97b 2010]

RM666.P415O98 2010

572'.65--dc22

2010014607

---

Visit the Taylor & Francis Web site at  
<http://www.taylorandfrancis.com>

and the CRC Press Web site at  
<http://www.crcpress.com>

# **BIOACTIVE PEPTIDES**

Applications  
for Improving  
Nutrition  
and Health

# Preface

Weight loss is a common reaction to infection, injury, or chronic disease. Many well-known host responses to illness contribute to muscle loss. Ensuring adequate lean body mass is of major concern in health care. Bioactive peptides and medical foods represent new approaches for addressing the metabolic derangements and nutritional deficits that contribute to unwanted weight loss. This book describes the latest research on the application of bioactive peptides for improving nutrition and health. We present the background science in Chapters 1 through 5 on the relations between illness and muscle weight loss. Chapters 6 through 9 deal with the use of bioactive peptides to modify aspects of the host response to illness, including inflammation, antimicrobial activity, anabolic dysfunction, and anorexia. The chapter titles are

- Chapter 1: Nutrition and the Host Response to Infection and Injury
- Chapter 2: Bioactive Peptides for Nutrition and Health
- Chapter 3: Dietary Protein Requirements for Health
- Chapter 4: Protein Turnover and Economics within the Body
- Chapter 5: Major Processes for Muscle Gain and Loss
- Chapter 6: Inflammation and Innate Immune Response
- Chapter 7: Infection and Sepsis
- Chapter 8: Anabolic Dysfunction
- Chapter 9: Bioactive Peptides for Alleviating Illness Anorexia

Evidence from *in vivo* studies and randomized clinical trials indicate that bioactive peptides can be effective in the prevention of weight loss associated with conditions such as aging, HIV/AIDS, burn injuries, chronic obstructive pulmonary diseases, diabetes, inflammatory bowel disease, kidney failure, and tuberculosis. Some of the approaches currently under development may be suitable for optimizing muscle growth and performance in otherwise healthy subjects. Parts of this book will be suitable reading for health-care professionals, including nutritionists, dietitians, food scientists, and technologists. The discussion will also be of interest to those interested in medical foods, nutraceuticals, and functional foods.

**Richard Owusu-Apenten**  
*University of Ulster  
Coleraine Campus*

---

# Acknowledgments

I am grateful to Nana Adwoa Amea (Nurse Ellen) for igniting my interest in weight loss. I thank my wife for her continued support. This book owes much to the stimulating atmosphere within the Northern Ireland Centre for Food and Health (NICHE), University of Ulster (County Londonderry, United Kingdom). My thanks to colleagues at the Coleraine campus for sparing their time to have valuable discussions with me. I am indebted to the front-desk staff at the British Library (St Pancras, London) where this journey ultimately began. Thanks also to Perundevi Dhandapani (SPi Publishing, Chennai, Tamil Nadu, India) for excellent editorial input. Lastly, I would like to thank the staff at Taylor & Francis, CRC Group (Boca Raton, Florida) for everything else.

---

# Author

**Richard Owusu-Apenten**, PhD, spent his early years in the newly independent ex-British colony of Gold Coast, Ghana, where he attended schools at Akim Oda, Bolgatanga, Kumasi, and Berekum. His interest in biology and chemistry was nurtured by further education in Quintin Kynaston High School, St. John's Wood, followed with BSc (Hons) and PhD degrees from the University of London. Dr. Apenten (Kwasi Owusu-Apenteng) spent four years as a postdoctoral research fellow in China, Wales, and University College London before taking up a lectureship in food science at Leeds University in 1989. From 2001 to 2005, Dr. Apenten had a fruitful stint as an associate professor at Penn State University before returning to the United Kingdom to pursue further interests in nutrition. Dr. Apenten is employed with the School of Biomedical Sciences, University of Ulster, at the Coleraine campus. He is an active member of both the Institute of Food Technology (IFT) and the American Chemical Society (ACS), and a fellow of the Institute of Food Science and Technology (IFST) (United Kingdom).

---

# Contents

Preface.....	xv
Acknowledgments.....	xvii
Author .....	xix
<b>Chapter 1 Nutrition and the Host Response to Infection and Injury .....</b>	<b>1</b>
1.1    Nutrition and Illness .....	1
1.1.1    Introduction .....	1
1.1.2    Infection and Undernutrition.....	2
1.1.3    Nutritional Status and Immune Function .....	2
1.1.4    The Undernutrition-Infection Paradigm.....	2
1.2    Host Response to Injury .....	3
1.2.1    The Ebb and Flow Phases .....	3
1.2.2    Molecular Aspects of the Host Response to Injury .....	3
1.2.3    The Infection-Inflammatory Response .....	5
1.2.4    Neuroendocrine Responses to Illness and Stress.....	5
1.3    Unintended Weight Loss .....	6
1.3.1    Sickness-Related Weight Loss .....	6
1.3.2    Illness Anorexia .....	7
1.3.3    Cachexia .....	8
1.3.4    Starvation Weight Loss versus Cachexia .....	10
1.3.5    Fat-Free Mass and Body Composition during Illness.....	11
1.3.6    Weight Loss and Mortality Risk .....	12
1.3.7    Premature or Preterm Infants.....	12
1.4    Multimodal Nutritional Support Using Bioactive Peptides....	13
1.4.1    Nutritional Support.....	13
1.4.2    Anti-Inflammatory Therapy and Wasting .....	13
1.4.3    Infection and Antisepsis.....	13
1.4.4    Anabolic Dysfunction .....	14
1.4.5    Anorexia and Food Intake.....	14
1.4.6    Antioxidant Capacity.....	14
1.5    Summary and Conclusions .....	14
References .....	16

<b>Chapter 2</b>	Bioactive Peptides for Nutrition and Health.....	21
2.1	Legislation .....	21
2.1.1	Introduction .....	21
2.1.2	Dietary Supplements .....	22
2.1.3	Foods for Special Medical Purposes.....	23
2.1.4	Medical Foods.....	24
2.1.5	EU Legislation for Dietetic Foods.....	26
2.1.6	Functional Foods.....	27
2.1.7	Protein and Peptide Medical Foods .....	29
2.2	Bioactive Peptides and Proteins .....	30
2.2.1	Bioactive Compounds.....	30
2.2.2	Bioactive Peptide–Related Nutritional Phenomena .....	31
2.2.2.1	Bioactive Peptides in Body Compartments.....	32
2.2.2.2	Exogenous Bioactive Peptides Associated with Foods.....	32
2.2.3	Gene-Encoded Bioactive Peptides .....	32
2.2.4	Bioactive Peptides and the Cryptome .....	33
2.2.5	Commercial Bioactive Peptides .....	34
2.2.6	Nutrigenomics Considerations .....	34
2.3	Applications of Protein Supplements for Health .....	35
2.3.1	Heterogeneous versus Enriched Supplements.....	35
2.3.2	Bone and Hip Fractures.....	36
2.3.3	Elderly Malnourished Patients .....	36
2.3.4	Pregnancy .....	37
2.3.5	Muscle Strength from Resistance Exercise .....	37
2.3.6	Insulin-Stimulating Activity .....	37
2.3.7	Protein Supplementation and Cardiovascular Health .....	38
2.4	Perspectives on Human Trial Data.....	39
2.4.1	Statistical Effects.....	39
2.4.2	Health Claims for Foods and Supplements .....	40
2.4.3	Safety and Side Effects of Bioactive Peptides and Proteins .....	41
2.5	Summary and Conclusions.....	41
	Appendices .....	42
	References .....	48

<b>Chapter 3</b>	Dietary Protein Requirements for Health .....	59
3.1	Introduction .....	59
3.1.1	Protein-Energy Undernutrition.....	59
3.1.2	Detection of Protein-Energy Undernutrition.....	60
3.1.3	Incidence and Consequences of Undernutrition .....	61
3.2	Dietary Protein Quality Relation to Health.....	62
3.2.1	Protein Quality and Nutritive Properties .....	62
3.2.2	Growth Assays for Dietary Protein Quality.....	63
3.2.3	Nitrogen Balance and Protein Quality .....	64
3.2.4	Dietary Protein Digestibility Relation to Nitrogen Balance.....	65
3.2.5	Ileal Digestibility and Net Postprandial Protein Utilization.....	66
3.2.6	Dietary and Body Protein Balances and Transformations.....	67
3.3	Protein Requirements and Health.....	68
3.3.1	Adults .....	68
3.3.2	Protein Requirements for Aging Adults (Elderly)....	69
3.3.3	Protein Requirements for Exercise.....	70
3.3.4	Preterm Infants and Children.....	70
3.4	Dietary Protein and Host Responses to Illness .....	71
3.4.1	Urea-Nitrogen Losses during Illness.....	71
3.4.2	Acute Phase Protein Synthesis .....	72
3.4.3	Protein EAA Imbalances during Illness .....	73
3.5	Peptides and Protein Bioactivity .....	75
3.5.1	Essential Amino Acid and Dietary Protein Meta-Nutrients .....	75
3.5.2	Leucine and the Branched Chain Amino Acids .....	77
3.5.3	Nutrient Signaling and Gene Interactions .....	78
3.5.4	Receptor Activation by Bioactive Peptides .....	79
3.5.5	Amino Acid Deprivation and Growth Retardation .....	79
3.5.6	Increased EAA Availability and Gene Expression .....	82
3.5.7	Microarray Profiling of Dietary Protein–Gene Interactions .....	82
3.6	Types of Dietary Protein Health Effects .....	84
3.6.1	Types of Health Benefits .....	84
3.6.2	Health Benefits and Non-Absorbed Proteins .....	84
3.7	Summary and Conclusion .....	85
	Appendices .....	85
	References .....	86

<b>Chapter 4</b>	Protein Turnover and Economics within the Body .....	97
4.1	Protein Turnover and Wasting .....	97
4.1.1	Introduction .....	97
4.1.2	Biological Purpose of Protein Turnover .....	97
4.1.3	Stable Isotope End Product and Precursor Flux .....	98
4.1.4	Non-Tracer Methods for Estimation of Turnover .....	100
4.1.5	Protein Turnover Implications for Nutritional Support .....	101
4.2	Baseline Whole Body Protein Turnover .....	102
4.2.1	Adults .....	102
4.2.2	Gender and Pregnancy .....	102
4.3	Regional Protein Turnover .....	103
4.3.1	Splanchnic Bed Protein Kinetics .....	103
4.3.2	First-Pass Metabolism of Dietary EAA and Interorgan Effects .....	104
4.4	Protein Turnover during Illness .....	105
4.4.1	Preterm Babies and Children .....	105
4.4.2	Aging Adults and Sarcopenia .....	106
4.4.3	HIV/AIDS Infection .....	107
4.4.4	Burns Patients .....	108
4.4.5	Cancer Cachexia .....	108
4.4.6	Chronic Renal Failure and Hemodialysis .....	110
4.4.7	Diabetes .....	110
4.4.8	Sepsis .....	112
4.4.9	Tuberculosis .....	112
4.4.10	Anabolic Dysfunction Affecting Protein Turnover .....	113
4.5	Nutrients and Protein Turnover .....	114
4.5.1	Dietary Protein Intake and Whole Body Protein Turnover .....	114
4.5.2	Skeletal Muscle Protein Turnover .....	116
4.5.2.1	Animal Studies .....	116
4.5.2.2	Effect of Nutrients on Skeletal Muscle Protein Turnover—Human Studies .....	118
4.6	Slow and Fast Proteins .....	119
4.6.1	Digestion and Absorption Kinetics .....	119
4.6.2	Effect of Fast Dietary Proteins on Protein Turnover .....	120
4.6.3	Intrinsic versus Extrinsic Contributions to Fast and Slow Proteins .....	122
4.6.4	Fast versus Slow Proteins for the Elderly and Young .....	123
4.6.5	Insulinotropic Action of Fast Proteins .....	123
4.7	Summary and Conclusions .....	124
	References .....	124

<b>Chapter 5</b>	<b>Major Processes for Muscle Gain and Loss .....</b>	<b>135</b>
5.1	Introduction .....	135
5.1.1	Muscle Cells .....	135
5.1.2	Muscle Stem Cell Proliferation .....	137
5.1.3	Muscle Stem Cell Differentiation.....	139
5.1.4	Nutrient Effects on Muscle Stem Cell Growth .....	140
5.2	Myostatin .....	140
5.2.1	Double Muscling and Myostatin Mutations .....	140
5.2.2	Myostatin Structure and Activity .....	141
5.2.3	Mode of Action of Myostatin .....	141
5.2.4	Myostatin Role in Wasting Diseases .....	142
5.2.5	Myostatin Inhibition as Therapy for Muscle Wasting.....	144
5.3	Muscle Cell Death and Atrophy .....	144
5.3.1	Types of Cell Death.....	144
5.3.2	Muscle Apoptosis and Necrosis .....	144
5.3.3	Skeletal Muscle Wasting via Apoptosis .....	146
5.3.4	Lysosome-Mediated Autophagy .....	147
5.4	Proteolysis via Ubiquitin Proteasome .....	149
5.4.1	Enzyme Systems for Muscle Wasting .....	149
5.4.2	Structure of the Ubiquitin-Proteasome .....	149
5.4.3	Ubiquitin Proteasome and Muscle Wasting .....	151
5.4.4	Cell Cycle Regulation and the Proteasome .....	151
5.4.5	UPS and the Immune Response.....	153
5.5	Further Signaling Pathways for Muscle Atrophy .....	153
5.5.1	Skeletal Muscle Differentiation Program.....	154
5.5.2	Nuclear Factor Kappa Beta and Muscle Wasting....	154
5.5.3	MuRF and Atrogin-1 Gene Expression.....	154
5.5.4	AKT/Foxo/Atrogin-1 Pathway and Proteolysis .....	155
5.5.5	Oxidative Stress and Muscle Wasting .....	158
5.5.6	Angiotensin-Related Muscle Wasting .....	158
5.6	Mammalian Target of Rapamycin and Hypertrophy .....	159
5.6.1	mTOR Function as a Nutrient Sensor .....	160
5.6.2	Two mTOR Complexes and Their Function.....	160
5.6.3	Regulation of Protein Synthesis by mTOR .....	162
5.7	Summary and Conclusions .....	162
	Appendices .....	162
	References .....	164

<b>Chapter 6</b>	Inflammation and Innate Immune Response .....	181
6.1	Types of Inflammation .....	181
6.1.1	Introduction .....	181
6.1.2	Acute and Chronic Inflammation.....	181
6.1.3	Infection Inflammation.....	184
6.1.4	Obesity-Related Inflammation .....	185
6.1.5	Chronic Inflammation, Illness, and Lifestyle Factors .....	187
6.2	Proinflammatory Signaling .....	188
6.2.1	Proinflammatory Cytokines.....	188
6.2.2	Transcription Factors for Inflammatory Signaling.....	189
6.2.3	Redox-Sensitive Inflammatory Transcription Factors .....	193
6.2.4	MAP Kinases, Phosphatases, and Inflammation ....	194
6.2.5	Renin–Angiotensin System and Inflammation .....	195
6.3	Anti-Inflammatory Bioactive Peptides and Supplements.....	197
6.3.1	Adiponectin .....	197
6.3.2	Angiotensin-Converting Enzyme Inhibitor Peptides .....	198
6.3.3	Antimicrobial Peptide Endotoxin Antagonists .....	199
6.3.4	Cytokine Antibodies .....	200
6.3.5	Ghrelin and Growth Hormone Secretagogues .....	200
6.3.6	Glucocorticoid-Inducible Peptides .....	202
6.3.6.1	Lipocortin or Annexin-1 .....	203
6.3.6.2	Uteroglobin or Clara Cell 10 Protein.....	204
6.3.6.3	Antiflammins.....	205
6.3.7	Map Kinase Inhibitors.....	205
6.3.8	Melanocortin Peptides and KPV .....	206
6.3.9	Glutamine and Glutamine Dipeptide .....	209
6.3.10	Food Proteins and Supplements .....	210
6.4	In Vivo Applications and Controlled Trials .....	211
6.4.1	Proof for Anti-Inflammatory Action.....	211
6.4.2	Inflammatory Bowel Disease, Colitis, and Mucosal Injury .....	212
6.4.3	Systemic Inflammatory Response and Sepsis.....	214
6.4.4	Respiratory Distress Syndrome, Lung Injury and Related.....	215
6.4.5	Rheumatoid Arthritis .....	217
6.5	Summary and Conclusions .....	218
	References .....	219

<b>Chapter 7</b>	<b>Infection and Sepsis .....</b>	<b>239</b>
7.1	Introduction .....	239
7.1.1	Bacterial Infections, Sepsis, and Weight Loss .....	239
7.1.2	Host Antimicrobial Peptides for Innate Defense .....	240
7.1.3	Antibiotics and Muscle Mass .....	241
7.2	Pathogen Recognition and Intracellular Signaling.....	242
7.2.1	Toll-Like Receptors.....	242
7.2.1.1	TLR in Peripheral Tissues and Muscles ...	243
7.2.1.2	Lipopolysaccharide Signaling via TLR4.....	245
7.2.1.3	Peptidoglycan Signaling via TLR2.....	245
7.2.1.4	Phagocytosis and TLR Function.....	246
7.2.2	NOD Intracellular Receptors for Pathogens.....	246
7.2.3	Toll Polymorphism and the Hygiene Hypothesis.....	246
7.3	Host Antimicrobial Peptides .....	247
7.3.1	General Properties.....	247
7.3.2	Defensins and Cathelicidins.....	248
7.3.2.1	Defensins .....	248
7.3.2.2	Cathelicidin or hCAP18.....	249
7.3.3	Dermaseptins and Frog Peptides.....	250
7.3.4	Bactericidal/Permeability-Increasing Protein.....	251
7.3.5	Lactoferrin, Lactoferricin, and Talactoferrin .....	252
7.4	Functions of Antimicrobial Peptides.....	253
7.4.1	Antibacterial Activity .....	253
7.4.2	Anticancer Activity of AMPs.....	253
7.5	In Vivo Applications and Human-Trials of AMPs.....	255
7.5.1	General Considerations .....	255
7.5.2	Burns Injury, Wound Healing .....	256
7.5.3	Cancer Therapy .....	256
7.5.4	Infant Diarrhea.....	257
7.5.5	<i>Helicobacter pylori</i> -Related Ulcers .....	257
7.5.6	Hepatitis C Treatment.....	258
7.5.7	Oral Mucositis .....	258
7.5.8	Ventilator-Associated Pneumonia .....	258
7.5.9	Sepsis and Endotoxemia.....	259
7.6	Summary and Conclusions .....	260
	Appendices .....	261
	References .....	265

<b>Chapter 8</b>	Anabolic Dysfunction .....	275
8.1	Introduction .....	275
8.1.1	Anabolic–Catabolic Imbalance.....	275
8.1.2	Anabolic Dysfunction Allied to Nutrient and Hormone Resistance.....	275
8.1.3	Protein Synthesis and Breakdown during Illness ....	277
8.2	Insulin and Muscle Protein Metabolism .....	278
8.2.1	Insulin Signaling .....	279
8.2.2	Insulin Resistance of Glucose Metabolism .....	281
8.2.3	Insulin Resistance of Muscle Protein Metabolism.....	282
8.2.4	Insulinotropic Bioactive Peptides.....	283
8.3	Growth Hormone and IGF-1 .....	285
8.3.1	Properties of Growth Hormone and IGF-1 .....	286
8.3.2	Growth Hormone Receptor Signal Transduction....	286
8.3.3	Biological Effects of Growth Hormone/IGF-1 Axis .....	287
8.3.4	Growth Hormone Resistance .....	287
8.4	Growth Hormone Secretagogues.....	289
8.4.1	Growth Hormone Release Peptides.....	289
8.4.2	Hexarelin and Alexamorelin .....	290
8.4.3	Ghrelin.....	292
8.5	Leucine, BCAA, and Related Peptides.....	294
8.5.1	Essential Amino Acids as Anabolic Agents .....	294
8.5.2	The Branched-Chain Amino Acids .....	294
8.5.3	Leucine .....	295
8.5.4	Whey Protein and Peptides .....	295
8.6	In Vivo Applications and Clinical Trials.....	296
8.6.1	Short Bowel Syndrome.....	296
8.6.2	HIV Patients .....	298
8.6.3	Chronic Renal Failure .....	300
8.6.4	Critical Illness and Sepsis .....	300
8.6.5	Cancer Cachexia and Muscle Wasting .....	301
8.6.6	Liver Disease .....	302
8.6.7	Adverse Effects and Safety Concerns .....	303
	References .....	304

<b>Chapter 9</b>	Bioactive Peptides for Alleviating Illness Anorexia .....	323
9.1	Illness Anorexia.....	323
9.1.1	Models for the Regulation of Food Intake .....	323
9.1.2	Bioactive Peptides and Energy Homeostasis.....	325
9.1.3	Anorectic Bioactive Peptides.....	325
9.1.4	Serotonin .....	326
9.1.5	Cytokines and Food Intake .....	327
9.2	Leptin and Food Intake .....	327
9.2.1	Characteristics of Leptin Receptor Signaling .....	327
9.2.2	Leptin Regulation of Food Intake .....	328
9.2.3	Leptin Resistance during Obesity .....	329
9.2.4	Leptin Role in Illness Anorexia .....	330
9.3	Melanocortin Peptides.....	331
9.3.1	Melanocyte-Stimulating Hormone.....	331
9.3.2	Melanocortin Networks to Leptin and Serotonin Signaling.....	331
9.3.3	Melanocortin Receptors .....	331
9.3.4	Peptide Agonists and Antagonists for Melanocortin Receptors .....	334
9.4	Ghrelin .....	337
9.4.1	Characteristics of Ghrelin .....	337
9.4.2	The Ghrelin Receptor.....	337
9.4.3	Factors Affecting Ghrelin Release .....	337
9.4.3.1	Ghrelin Circadian and Ultradian Rhythms.....	340
9.4.3.2	Food Intake .....	341
9.4.3.3	Macronutrient Composition.....	341
9.4.3.4	Hormones and Ghrelin Secretion .....	341
9.4.3.5	Ghrelin and Obesity.....	342
9.4.3.6	Fasting Weight Loss.....	342
9.4.3.7	Aging and Ghrelin Secretion.....	343
9.4.3.8	Cachexia .....	344
9.4.4	Exogenous Ghrelin and Food Intake.....	345
9.4.5	Mode of Ghrelin Orexigenic Action .....	346
9.5	Other Bioactive Peptides for Moderating Appetite .....	346
9.5.1	Agouti-Signaling Protein and AgRP.....	347
9.5.2	Neuropeptide Y .....	348
9.5.3	Serotonin Antagonists .....	348
9.5.4	Dietary Proteins and Satiety .....	349
9.6	In Vivo Studies and Controlled Trials.....	351
9.6.1	Cancer Anorexia.....	351
9.6.2	Pulmonary Obstructive Disease .....	352
9.6.3	Chronic Kidney Failure and Dialysis Patients .....	352
9.6.4	HIV Infection Anorexia .....	353

9.6.5 Melanocortin Antagonists for Anorexia Treatment.....	353
9.7 Summary and Conclusions .....	354
References .....	355
<b>Index.....</b>	<b>369</b>